You are here: Industry Insights > Umifenovir

News List

SEC asks CDSCO to submit adverse event report of death during Umifenovir trial expresspharma
October 16, 2020
The Subject Expert Committee (SEC) has asked CDSCO to submit data of the reported serious adverse event (SAE), a single death, from the clinical trials of the drug combination of Favipiravir + Umifenovir by Glenmark Pharmaceuticals.
Umifenovir addition gives no significant clinical benefit in COVID-19 treatment: Glenmark study expresspharma
October 10, 2020
The FAITH study enrolled a total of 158 hospitalised patients with moderate COVID-19 in India.
CDRI gets approval for Phase III trial of Umifenovir to treat Covid-19 pharmaceutical-technology
June 22, 2020
Central Drug Research Institute (CDRI), a constituent lab of India-based Council of Scientific and Industrial Research (CSIR), has secured approval for carrying out Phase III trial for the use of Umifenovir in the treatment of Covid-19.
Umifenovir gets DCGI nod for Phase III clinical trial against COVID-19 expresspharma
June 19, 2020
CSIR-CDRI has developed the process technology for Umifenovir and licensed the process technology for manufacturing and marketing of the drug to Medizest Pharmaceuticals, Goa, which has already received test license from DCGI.
Glenmark Begins Phase III Trial of Anti-Viral Combo in COVID-19 contractpharma
May 27, 2020
To test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment.